Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alnylam partners ALNRSV01 with Kyowa in Asia

Executive Summary

In its second tie-up with a Japanese pharmaco in less than a month, RNA interference specialist Alnylam Pharmaceuticals has granted Kyowa Hakko Kogyo exclusive rights to develop and market its lead therapeutic ALNRSV01 for respiratory syncytial virus (RSV) in Japan and other Asian countries.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Nasal
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register